James L. Wisecarver M.D., Ph.D. Associate Professor - the Nebraska ...

4/00HOME AND CAMPUS ADDRESS:James L. Wisecarver M.D., Ph.D.Associate ProfessorHome:4311 North 154th AvenueOmaha, NE 68116(402) 491-0561Campus:Department of Pathology and MicrobiologyUniversity of Nebraska Medical Center983135 Nebraska Medical CenterOmaha, NE 68198-3135Phone: 402-559-4618Fax: 402-559-6018E-mail: jwisecar@unmc.eduEDUCATION AND TRAINING:College:Doane CollegeCrete, NebraskaGraduated - May, 1972Bachelor of Arts - BiologyGraduate School:Creighton UniversityOmaha, NebraskaAugust, 1974 - December, 1978Ph. D. - PhysiologyMedical School:University of NebraskaOmaha, NebraskaAugust, 1982 - May, 1986M. D. degree conferred - May, 1986Residency :House Officer; Department of PathologyUniversity of Nebraska Medical CenterOmaha, NebraskaJuly, 1986 - June, 1990Chief Resident:Department of PathologyUniversity of Nebraska Medical CenterOmaha, NebraskaJuly, 1989 - June, 1990

James L. Wisecarver, M.D., Ph.D.Page 2ACADEMIC APPOINTMENTS:Assistant Professor, Department of Pathology-Microbiology, 1990- 1995Graduate Faculty Fellow, Graduate School, UNMC, 1992 - presentAssociate Professor, Department of Pathology-Microbiology, 1995- presentTenure granted July, 1998INTERESTS AND RESPONSIBILITIES:Medical Director, NHS Molecular Diagnostics LaboratoryMedical Co-Director, NHS Clinical LaboratoriesConsulting Medical Director, Nebraska State Health LaboratoryNHS Morbidity and Mortality CommitteeMedical Advisory Committee, Nebraska Organ Retrieval SystemMember, Board of Directors, Nebraska Organ Retrieval SystemMember, Board of Directors - Streck LaboratoriesHONORS:Alpha Sigma Nu - Nat. Jesuit Honor Soc., Creighton ChapterAlpha Omega Alpha - University of Nebraska ChapterUniversity of Nebraska Regents Scholarship - 1983-1984Sandoz Pharmaceutical Scholarship - 1985-1986Honorable Mention - Sheard-Sanford Award for Medical Student Research;sponsored by the American Society of Clinical Pathologists -1984Finalist, Resident Research Award Competition ASCP/CAP Spring Meeting, 1990.Diplomate, American Board of Pathology Anatomic and Clinical Pathology; June 9, 1991TEACHING:Medical General Pathology Course - lecturesInflammation and Repair (Aug- Sept)Gastrointestinal Pathology – Liver (April)Medical Student General and Clinical path small groups and PBL sessions.Medical Student Laboratory sessionsPathology lectures in Biology of Disease course (Allied Health students)PROFESSIONAL SOCIETIES AND EDITORIAL BOARDS:American Society of Clinical Pathologists, 1994-2000Member- Council on Diagnostic Immunology and Molecular PathologyFellow- College of American PathologistsU.S. and Canadian Academy of PathologyNebraska Association of PathologistsSec-Treasurer - 1993-94Program Coordinator - 1995-96Association for Molecular PathologyAmerican Society for Histocompatibility and Immunogenetics (ASHI)Clinical Laboratory Management Association (CLMA)Academy of Clinical Laboratory Physicians and Scientists

James L. Wisecarver, M.D., Ph.D.Page 3PROFESSIONAL SOCIETIES AND EDITORIAL BOARDS (Continued):Editorial Board - American Journal of Clinical PathologyAd Hoc reviewer - American Journal of Gastroenterology“What’s new in GI” section contributorCancer ResearchLiver Transplantation and SurgeryCLINICAL SERVICE:Transplant biopsy service (liver, small bowel and pancreas, occ. renal)Surgical Pathology – NHS UniversityMedical Director, Molecular Diagnostics LaboratoryConsulting Medical Director, Nebraska State Health LabsMedical Co-Director NHS Clinical LaboratoriesConsultant Staff Pathologist, Omaha Veterans Affairs Medical CenterRESEARCH:Transplantation immunology and immunogenetics (solid organ and hematopoietic)Molecular identity testing using short tandem repeat analysisFUNDING:Research Contract MWT 17-207-62201 (Hybritech) - 1992Grant Title: HLA Class II Antigen Association with Myocarditis andCardiomyopathy”Funding Agency: American Heart Association Grant-in-aid, 1994Start & End Dates: July, 1994-June, 1995Total Dollars (Direct Cost): $20,000Name of PI: James Wisecarver, M.D., Ph.D.Grant Title: SPORE in Gastrointestinal Cancer (Optimizingradioimmunotherapy for pancreatic cancer)Funding Agency: NCI/NIH 1P50CA72712Start & End Dates: 9/1/97-8-31-98 9/1/97-8/31/2000Total Dollars (Direct Cost): $ 559,850 Total $1,716,772Names of PI and Co-PI: Dr. Tempero, P.I.; Co-PI Jim Anderson, Sam Augustine,Janna Baranowska-Kortylewicz, Dave Colcher, Lisa Gobar, James WisecarverGrant Title: Enhanced Laboratory Preparedness: Responding to the Threat of BioterrorismFunding Agency, Nebraska Health and Human ServicesStart & End Dates: 09/15/99-09/14/00Total Dollars (Direct Cost): $107,500Name of PI: James Wisecarver, M.D., Ph.D.

James L. Wisecarver, M.D., Ph.D.Page 4PUBLICATIONS:1. Goodnow RA, Lehr C, Shade FJ, Wisecarver JL: Mouse potency assay for Bordetellabronchiseptica bacterins. J Clin Microbiol 1977; 6:337-339.2. Sullivan JF, Williams RV, Wisecarver JL, Etzel K, Jetton MM, Magee DF: The zinc content ofbile and pancreatic juice in zinc-deficient swine. Proc Soc Exper Biol Med 1981; 166:39-43.3. Wisecarver JL, Etzel K, Magee DF: A study of gastric secretion in dogs using pilocarpine. JAutonomic Pharmacol 1981; 1:141-147.4. Etzel K, Wisecarver JL, Magee DF: Catecholamines and the cephalic phase of gastricsecretion. Canadian J Physiol Pharmacol 1981; 59:1189-1191.5. Etzel K, Wisecarver JL, Magee DF: Exogenously stimulated gastric secretion in dogs afterganglion and sympathetic blockade and antral acidification. J Autonomic Pharmacol 1982;2:45-51.6. Pappas NJ, Wisecarver JL, Becker SJ: Effect of cyclohexamide on increased aspartateaminotransferase in carbon tetrachloride hepatotoxicity. Ann Clin Lab Sci 1984; 14:40-46.7. Wisecarver JL, Bechtold T, Lipscomb H, Davis J, Collins M, Sonnabend JA, Purtilo DT: Amethod for determination of antibody-dependent cellular cytotoxicity (ADCC) of humanperipheral mononuclear cells. J Immunol Methods 1985; 79:277-282.8. Wisecarver JL, Bechtold T, Lipscomb H, Davis J, Collins M, Sonnabend JA, Purtilo DT:Comparison of ADCC and NK activities of peripheral blood mononuclear cells from patients atrisk for acquired immune deficiency syndrome (AIDS). AIDS Research 1984; 1:347-352.9. Wisecarver JL, Jones JW, Goaley T, McManus B: Fatal coronary artery dissection: Thechallenge of detection, the enigma of cause. Am J Forensic Med 1989; 10:60-62.10. Wisecarver JL, Harrington D: Bone marrow necrosis obscuring the diagnosis of acutepromyelocytic leukemia. Hematol Pathol 1988; 2:51-54.11. Wisecarver JL, Ness MJ, Rennard SI, Thompson AB, Armitage JO, Linder J: Bronchoalveolarlavage in the assessment of pulmonary Hodgkin's disease. Acta Cytol 1989; 33:527-532.12. Wisecarver JL, Haire WD: Disseminated intravascular coagulation with multiple arterialthromboses responding to Antithrombin III concentrate infusion. Thrombosis Res 1989; 54:709-717.13. Wisecarver J, Jones J, Goaley T, McManus B: “Spontaneous” coronary artery dissection. Thechallenges of detection, the enigma of cause. Am J Forenssic Med Pathol 199, 10:60-62.14. Wisecarver JL, Haven MC, Markin RS: A macro-driven Lotus 1-2-3 template for calculating andplotting receiver-operator characteristic curves for clinical laboratory tests. Computers in BiolMed 1990; 20;121-127.15. Ogren FP, Wisecarver JL, Lydiatt DD, Linder J: Ancient neurilemmoma of the infratemporalfossa: A case report. Head and Neck Surgery 1991; May/June: 243-246.16. Rubocki RJ, Wisecarver JL, Hook DD, Cox SM, Beisel KW: Histocompatibility screening bymolecular techniques: Use of PCR products and heteroduplex formation. J Clin Lab Anal 1992;6:337-341.

James L. Wisecarver, M.D., Ph.D.Page 517. Wisecarver JL, Earl RA, Haven MC, Timmons PW, Shaw BW Jr, Stratta RJ, Langnas AN,Zetterman RK, Donoval JP, Shaefer MS, et al: Histologic changes in liver allograft biopsiesassociated with elevated whole blood and tissue cyclosporine concentrations. Mod Pathol 1992;5:611-616.18. Wisecarver J, Shepherd S, Beisel K, Rubocki R.: Serologic and molecular studies of twokindreds expressing recombinant HLA DR1/DR2 haplotypes. Tissue Antigens 1993; 41:148-154.19. Wisecarver J, Synovec M, Pirruccello S, Linder J. Marking characteristics of anti-nuclear matrixprotein NM200.4 in human breast carcinomas and normal human tissues. J Clinical Lab Anal1993; 7:134-138.20. Wisecarver JL, Linder J: The pathology interest group: A tool for recruiting medical studentsinto pathology. Lab Med 1993; 24:512-514.21. Galati J, Quigley E, Wisecarver J: Inflammatory polyps as a manifestation of intestinal graftvs-hostdisease. Gastrointestinal Endoscopy 1993; 39:719-722.22. Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW Jr.: Frozensection evaluation of donor livers prior to transplantation. Transplantation 1993; 56:1403-1409.23. Sisson JH, Papi R, Beckmann JD, Leise K, Wisecarver J, Broderson B, Kelling CL, Spurzem JR,Rennard SI: Smoke and viral infection cause cilia loss detectable by bronchoalveolar lavagecytology and dynein ELISA. Am J. Resp Crit Care Med 1994; 149:205-213.24. Rubocki RJ, Langnas AN, Degenhardt J, Shepherd S, Catrall M, Shaw BW Jr, Wisecarver, JL:The origin of lymphocytes in donor-derived lymph nodes following combined liver/small boweltransplantation. Transplantation, 1994; 57:303-306.25. Radio SJ, Stratta RJ, Linder J, Wisecarver JL, Taylor RJ, Markin RS: Histologic confirmation ofacute rejection detected by urine cytology in pancreas transplant recipients. Transplant Proc,1994; 26:529-530.26. Wisecarver JL, Radio SJ, Shaw BW, Jr. Langnas AN, Markin RS: Intrahepatic arteriopathyassociated with primary non-function of liver allografts. Hum Pathol, 1994; 25:960-963.27. Cattral MS, Langnas AN, Wisecarver JL, Harper JC, Rubocki RJ, Bynon JS, Fox IJ, Heffron TG,Shaw BW Jr: Survival of graft-vs-host disease in a liver transplant recipient.Transplantation, 1994; 57:1271-1274.28. Wisecarver JL, Cattral MS, Langnas AN, Shaw BW,Jr., Fox, IJ, Heffron TG, Rubocki RJ:Transfusion-induced graft-versus-host disease following liver transplantation: Documentationusing polymerase chain reaction with HLA-DR sequence specific primers. Transplantation,1994; 58: 269-271.29. Stratta RJ, Taylor RJ, Grune MT, Sindhi R, Sudan D, Castaldo P, Cushing KA, Radio SJ,Wisecarver JL, Matamoros A, Nelson NL , Hapke MR , Pillen TJ, Markin RS: Experience withprotocol biopsies after solitary pancreas transplantation. Transplantation 1995; 60:1431-37.30. Rubocki RJ, Berrigan BE, Speaks SL, Wisecarver JL. Locus-specific de novo methylation downregulates MHC class I in S49 lymphomas. Immunogenetics 1996; 43:63-67.31. Swartz S, Wisecarver J, Bridge JA: Significance of extra copies of chromosome 20 and the longarm of chromosome 2 in hepatoblastoma. Cancer Genet Cytogenet 1996; 91:65-67.

James L. Wisecarver, M.D., Ph.D.Page 632. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Wisecarver J, LinderJ, Colcher D. High dose therapy with 131 I labelled monoclonal antibody CC49: A phase I trial.J Clin Oncol 1997; 15:1518-1528.33. Lepley DM, Gillanders WE, Myers NB, Robinson RA, Beisel KW, Wisecarver JL, Pirruccello SJ,Lee DR, Hansen TH, Rubocki RJ: Biochemical and functional characterization of solublemultivalent MHC L d /Fc gamma 1 and L d /Fcµ chimeric proteins loaded with specific peptides.Transplantation 1997; 63:765-774.34. Wisecarver JL: The ABCs of DNA: The basic properties of DNA. Lab Medicine 1997; 28.35. Wisecarver JL: The ABCs of DNA: Techniques used to test native DNA. Lab Medicine 1997;28:817-821.36. Wisecarver JL: The ABCs of DNA: Amplification. Lab Medicine 1997; 28:191-195.37. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine S, Wisecarver J, Tempero MA: Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 1997; 38:512-516.38. Lozano MD, Rubocki RJ, Wilson JE, McManus BM, Wisecarver JL. Human leukocyte antigenclass II associations in patients with idiopathic dilated cardiomyopathy. J Cardiac Failure1997; 3:97-103.39. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Anderson J,Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibodyCC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 1997, 15:1518-12840. Kaufman S, Wisecarver JL, Ruby EI, Fox IJ, Sudan DL, Pillen TJ, Dhawan A, Horslen SP,Vanderhoof JA, Radio SJ, Markin RS, Langnas AN. Correlation of mucosal disaccharidaseactivities with histology in evaluation of rejection following intestinal transplantation.Pediatr Transplantation 1998; 2:134-138.41. Wisecarver JL, Adloff VC, McCue BJ, Rubocki RJ. Molecular techniques for the identification ofprocessed tissues. ASCP Check Sample No. MDI 98-1; June 199842. Wisecarver JL: HER-2/neu testing comes of age. (Editorial) Am J Clin Pathol, 1999; 111:299-301.43. Randak C, Langnas AN, Kaufman SS, Phillips AD, Wisecarver JL, Hadron H-B, VanderhoofJA: Pretransplant management and small bowel-liver transplantation in an infant withmicrovillous inclusion disease. J Pediatr Gastroenterol Nutr 1998; 27:333-337.44. Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL,Rabkin JM, Lee WM. The Acute Liver Failure Study Group. Acute liver failure associated withprolonged use of bromofenac leading to liver transplantation. Liver Transplant Surg 1999,5:480-484.ARTICLES ACCEPTED FOR PUBLICATION:1. Rubocki RJ, Duffy KJ, Shepard KL, McCue BJ, Shepherd SJ, Wisecarver JL. Loss ofheterozygosity detected in a short tandem repeat (STR) locus commonly used for human DNAidentification. J Forensic Sci (Accepted for publication).

James L. Wisecarver, M.D., Ph.D.Page 7ARTICLES SUBMITTED FOR PUBLICATION:1. Strong ML, Ueda CT, Wisecarver. Renal cyclosporine A disposition in the isolated perfused ratkidney. J Pharmacokinet Biopharm (Submitted).2. Rubocki RJ, McCue, BJ, Duffy KJ, Shepard KL, Shepherd SJ, Wisecarver JL. Natural DNAmixtures generated in fraternal twins in utero. (Submitted with revisions).3. Cauble MS, Donovan JP, Sorrell MF, Mailiard ME, Sudan DL, Anderson JA, Wisecarver JL,Balakrishnan S, Larsen JL. Lipoarophic diabetes and end-stage liver disease secondary to nonalcoholicsteatohepatitis with recurrence following liver transplantation (Submitted).BOOKS AND CHAPTERS:1. Markin RS, Radio SJ, Wisecarver JL: Transplant Pathology. ASCP Press, 1994.2. Sell S, Wisecarver JL; Immunopathologic Mechanisms ; In: Damjanov and Linder. Anderson'sTextbbook of Pathology. pp. 548-590, St. Louis, Mosby 1996.ABSTRACTS:1. Goodnow RA; Imming C; Otten J; Wisecarver J: Characterization of Bordetella bronchisepticavirulent determinants. ; 81st Annual meeting; American Society of Microbiology; Dallas, TX;1981.2. Pappas NJ; Wisecarver JL; Garman SJ: Synthesis causing liver and serum aspartateaminotransferase rise after carbon tetrachloride. Clin Chem 1982; 28:1605.3. Bechtold T; Wisecarver JL; Lipscomb H; Sonnabend JA; Purtilo DT: A method for determiningantibody-dependent cellular cyto-toxicity (ADCC) using an established cell line andcommercially available antisera. Fed Proc 1984; 43:1444.4. Haven M; Radio SJ; Wisecarver JL; Markin RS: Receiver-operator characteristic curve analysisof creatine phosphokinase isoenzymes in the assesment of acute myocardial infarction. ClinChem 1988; 34:5. Jones JW; Wisecarver JL; McManus B: Primary coronary artery dissection: Characterizationand clues to pathogenesis. XVII. International Congress International Academy of Pathology.Dublin; Ireland August; 1988.6. Wisecarver JL; Kendall TJ; Costanzo-Nordin MR; Winters GL; Switzer BL; McManus BM:Soluble IL-2 receptor proteins in human heart allograft recipients: Relationship to frequencyand intensity of rejection. Second International Symposium on Inflammatory Heart Disease;Snowmass Conference Center; July; 1988.7. Collins M; Wisecarver JL; Casey J; Chakraborty AK; Pirrucello SJ: Correlation of peripheralblood monitoring for rejection and biopsy results in cardiac transplant patients. ClinicalImmunology Society 1988 meeting.8. Wisecarver JL; Ness MJ; Rennard SI; Armitage J; Linder J: Bronchoalveolar lavage in theassessment of pulmonary Hodgkin's disease. Annual Scientific Meeting; American Society ofCytology; November 1 - 6; 1988.

James L. Wisecarver, M.D., Ph.D.Page 89. Tritz D; Wisecarver J; Casey J; Linder J: Image analysis of fine needle aspirates (FNA) ofprostatic adenocarcinoma. Modern Pathol 1989; 2:97a.10. Wisecarver JL; Wood RP; Shaw BW; Zetterman RK; Markin RS: Histologic changes in biopsiesof hepatic allografts associated with elevated whole blood cyclosporine A concentrations.Modern Pathol 1989; 2:106a.11. Wisecarver J; Thompson A; Rennard S; Armitage J; Linder J: Imaging cytometry of Reed-Sternberg cells in bronchoalveolar lavage specimens. Presented at the Annual ScientificMeeting; American Society of Cytology; November; 1989; Louisville; KY.12. Wisecarver JL; Masada CT; Haven MC; Pirruccello SJ; Linder J: Technical considerations of c-erb B-2 oncoprotein immunohistochemistry in breast carcinomas: An imaging cytometryapproach. Modern Pathol. 1990; 3:107a.13. Masada CT; Wisecarver JL; Haven MC; Linder J: Quantitative immunohistochemistry ofhormone receptors in breast carcinoma. Modern Pathol. 1990; 3:63a.14. Wisecarver JL; Haven MC; Shaw BW Jr; Wood RP; Stratta RJ; Langnas AN; Zetterman RK;Donovan JP; Markin RS: Ultrastructural changes in biopsies from liver allografts associatedwith elevated whole blood cyclosporine A concentrations. Modern Pathol. 1990; 3: 107a.15. Linder J; Wisecarver JL; Synovec MS: Digital images in pathology-Perspectives of academicpathology departments. Modern Pathol. 1990; 3:58a.16. Markin RS; Wisecarver JL; Wood RP; Langnas AN; Stratta RJ; Duckworth RD; Radio SJ:Frozen section evaluation of donor livers prior to use for transplantation. Modern Pathol. 1990;3:63a.17. Wisecarver JL; Earl R; Haven MC; Timmons P; Markin RS: Histologic manifestations ofcyclosporine therapy in Liver allografts. Am J Clin Path. March; 1990.18. Wisecarver JL; Synovec MS; Pirruccello SJ; Linder J: Image analysis of immunohistochemicalmarking of breast carcinoma using anti-nuclear matrix protein NM 200.4. Modern Pathol. 199119. Von Essen SG; O'Neill D; Wisecarver JL; Rennard S; Robbins R: Grain sorghum dust extractcauses lymphocyte chemotaxis directly and by stimulating bronchial epithelial cells to secretechemotactic activity. Am Thoracic Soc./Am Lung Soc 1991 annual meeting.20. Bottjen P; Haven M; Wisecarver J; O'Connor S; Noel S; Markin R: Receiver-Operatorcharacteristic curves of fetal lung maturity on amniotic fluid. Am Assn Clin Chem. Summer;199021. Kolbeck PC; Wood RP; Shaw BJ Jr; Wisecarver JL; Markin RS: The clinical utility of T-cellculture for liver transplant biopsies. XIII International Congress of the Tranplantation Society;San Francisco; CA. August; 199022. Wisecarver J; Hurkman D.: Comparative study: Preservation of antigenic sites post-fixation intissues. Presented at ASCP Spring Meeting ; Nashville TN; March 1991.23. Broderson BW; Sisson JH; Wisecarver JL; Thompson AB; Rennard SI; Kelling CL.Differentiation of bronchial and alveolar samples from bronchoalveolar lavage of cattle. 12thAnnual Food Animal Disease Research Conference; May 1991.

James L. Wisecarver, M.D., Ph.D.Page 924. Wisecarver; JL; Broderson BW; Kelling; C; Liese; K; Cano; M; Sisson; J: Smoke-induced injuryto bronchial epithelium: Cytologic and ultrastructural changes. Lab Invest 66:117A; 1992.25. Masada CT; Dobson JR; Wisecarver JL; Markin RS; Linder J: Histologic features guiding theappropriate use of cytomegalovirus immunohistochemistry. Modern Path 5:46A; 1992.26. Wisecarver JL; Hook D; Shepherd S; Rubocki R: Novel HLA DR haplotypes determined bypolymerase chain reaction and oligonucleotide probes. Lab Invest 66:122A; 1992.27. Wisecarver J; Hook D; Rubocki R: Large scale molecular screening strategies for HLA Class IIloci for allogeneic bone marrow transplantation. Lab Invest 1992; 66:122A.28. Wisecarver J; Linder J: Pathoblasts: a tool for recruiting Medical Students into Pathology.ASCP Fall Meeting; Las Vegas; NV; Oct. 199229. Knott K; Shepherd S; Hook D; Davidson M; Rubocki R; Wisecarver J: Donor selection for aprospective allogeneic bone marrow transplant patient with an unusual HLA Class II antigen.18th Annual ASHI meeting; October 1992; Kansas City; MO.30. Shepherd S; Wisecarver J; Hook D; Beisel K; Rubocki R: The presence of a HLA DR triplet(DR1/2; DR3 or DR7) confirmed by serological and molecular testing. 18th Annual ASHImeeting; October 1992; Kansas City; MO.31. Hook D; Cox S; Wisecarver J; Rubocki R: Polymerase chain reaction and restriction fragmentlength polymorphism to identify the HLA-DR-BR allele. 18th Annual ASHI meeting; October1992; Kansas City; MO.32. Cox S; Hook D; Rubocki R; Wisecarver J; Beisel K: Histocompatibility screening of allogeneicbone marrow transplant recipients and donors using molecular techniques: PCR products andheteroduplex formation. Submitted for 18th Annual ASHI meeting; October 1992; Kansas City;MO.33. Duffy K; Shepherd S; Rubocki R; Wisecarver J. Lymphocyte origin in donor-derived nodesfollowing combined liver/small bowel transplantation. 19th Annual ASH meeting; October1993; Phoenix; AZ.34. Lepley D; Berrigan B; Pirrucello S; Wisecarver J; Rubocki R: Chimeric MHC Class I-immunoglobulin gene constructs as modulators of the immune response. AAI/CIS 1993 meeting.35. Wisecarver J; Radio S; Shaw BW Jr; Langnas A; Fox I; Heffron T; Markin R: Intrahepaticarteriopathy associated with primary non-function of liver allografts. Modern Pathol 1993;6:115A.36. Wisecarver J; Rubocki R; Kloster T; Knott K; Shaw BW Jr; Langnas AN; Markin RS: Acutegraft-vs-host disease following liver transplantation: Demonstration of circulating donor cellsin the peripheral blood using VNTR analysis. Mod Pathol 1993; 6:142A.37. Dobson JR; Stratta RJ; Treves J; Langnas AN; Radio SJ; Wisecarver JL; Shaw BW Jr; Markin RS:Autopsy following liver transplantation: An experience with 107 cases. Mod Pathol 1993;6:109A.38. Markin RS; Monsour H; Stratta RJ; Hirst K; Ranjan D; Donovan JP; Sorrell MF; Zetterman RK;Langnas AN; Wisecarver JL; Radio RJ; Shaw BW Jr.: A case control study of chronic rejection inliver transplant recipients: Results of a multivariate analysis. Mod Pathol 1993; 6:112A.

James L. Wisecarver, M.D., Ph.D.Page 1039. Radio SJ; Stratta RJ; Wisecarver JL; Taylor RJ; Markin RS: Transplant arteriopathy in pancreasallografts: An intimal proliferation contributing to early and late graft failure. Mod Pathol1993; 6:113A.40. Radio SJ; Stratta RJ; Taylor RJ; Linder J; Wisecarver JL; Markin RS: Histologic Confirmation ofAcute Rejection in Pancreas Transplants Initially Detected by Urine Cytology. ICPIT 1993meeting.41. Wisecarver JL; Shepherd SJ; McCue B; Shaw BW; Jr.; Langnas; AN; Rubocki RJ: Graft versushost disease related to blood transfusion following liver transplantation: Detection using RFLPand PCR-SSP techniques. 1993 ASHI National Meeting; Phoenix; AZ42. Lepley DM; Berrigan BE; Pirruccello S; Wisecarver J; Rubocki RJ: Chimeric MHC Class I-immunoglobulin gene constructs as modulators of the immune response. 1993 ASHI NationalMeeting; Phoenix; AZ43. Cattral M; Langnas A; Wisecarver J; Rubocki R; Fox I; Heffron T; Bynon J; Sorrell M; Donovan J;Shaw Jr. B: Transfusion-associated graft-vs-host disease after liver transplantation.American Association for the Study of Liver Diseases. Annual Meeting; November 1993.44. Wisecarver JL; Rubocki RJ; Larsen AE; Shepherd SJ; Langnas AN; Heffron T; Fox IJ; Shaw BWJr.; Markin RS: Factors affecting liver allograft survival: A study of 622 transplant recipients.Mod Pathol 1994; 7:137A.45. Lozano MD; Wisecarver JL; Rubocki RJ; Wilson; J; McManus BM.; and the MyocarditisTreatment Trial Investigators. HLA-class II associations in patients with myocarditis anddilated cardiomyopathy. Mod Pathol 1994; 7:29A.46. Wisecarver JL; Rubocki RJ; Langnas AN; Cattral MS; Shaw BW Jr.; Radio SJ; Markin RS:Graft-vs-host disease (GVHD) following liver transplantation: Molecular diagnostic tools fordetermining the origin of donor cells. Mod Pathol 1994; 7:137A.47. Kendall T; Radio SJ; Stratta RJ; Taylor; RJ; Wisecarver JL; Markin RS. Confirmation of acutepancreas rejection by core biopsy in patients monitored by urine cytology. Mod Pathol 1994;7:132A.48. Dobson JR; Fox IJ; Langnas AN; Heffron TG; Shaw BW Jr; Radio SJ; Wisecarver JL; Markin RS:The histopathology of homologous extracorporeal livers. Mod Pathol 1994; 7:131A.49. Wisecarver JL; Larsen AE; Shepherd SJ; Hauder CJ; Langnas AN; Shaw BW; JR.; Impact ofHLA matching on liver allograft rejection. Hum Immunol 1994; 40 (Suppl): 6.50. Rubocki RJ; Berrigan B; Shepherd S; Wisecarver J; The role of DNA methylation in the downregulationof MHC class I in a series of murine lymphoma variants. Hum Immunol 1994; 40(Suppl): 60.51. Cox S; Shepherd S; Rubocki R; Wisecarver J; Incompatible lymphocyte crossmatch is predictiveof poor outcome in liver allografts. Hum Immunol 1994; 40 (Suppl): 7.52. Shepherd S; Cox S; Rubocki R; Wisecarver J; A DRB1 07 with a DRB4 gene deletion identifiedin an unrelated bone marrow transplant recipient. Hum Immunol 1994; 40 (Suppl): 61.53. McCue-Doerneman B; Hook D; Shepherd S; Wisecarver J; Rubocki R; A rapid method of HLAClass II typing with sequence-specific primers using 96-well tray format. Hum Immunol 1994; 40(Suppl): 154.

James L. Wisecarver, M.D., Ph.D.Page 1154. Hook D; Shepherd S; Wisecarver J; Rubocki R; DRB3 typing by polymerase chain reactionfollowed by restriction fragment length polymorphism. Hum Immunol 1994; 40 (Suppl): 156.55. Rubocki RJ; Lepley BE; Berrigan BE; Myers N; Robinson R; Wisecarver JL; Pirrucello S; Lee D;Hansen TH. Conformational studies of soluble multivalent murine MHC Ld/Fcg1 and Ld/Fcmchimeric proteins. 9th International Congress of Immunology; July; 1995.56. Stratta R; Taylor R; Grune M; Sindhi R; Sudan D; Castaldo P; Cushing K; Radio S; WisecarverJ; Markin R; Experience with protocol biopsies after solitary pancreas transplantation (SPTx).7th Congress of the Society for Organ Transplantation; Vienna Austria; October; 1995.57. Duffy K; McCue B; Hook D; Mountjoy C; Rubocki R; Wisecarver J. Indications for furtherevaluation of DR typing obtinaed by sequence specific primers. 21st Annua ASH meeting;October; 1995; Dallas; TX.58. Gutkin DG; Rubocki RJ; Wisecarver JL; Evaluation of alkaline phosphatase gene expression inneoplastic and non-neoplastic liver diseases by in situ RT-PCR. Submitted for 1996 SpringASCP/CAP meeting in Boston; MA.59. Radio SJ; Wisecarver JL; Markin RS; Taylor RJ; Gill I; Stratta RJ. Differentiating ischemiafrom rejection of duodenal segment after pancreas transplantation with bladder drainage. AmSoc Tranplant Physicians. 15h annual meeting May 1996.60. Heffron T; Langnas A; Mack D; Wisecarver J; Fox I; Dhawan A; Kaufman S; Sudan D; Jerius J;Pillen T; McCashland T; Antonsen D; Markin R; Vanderhoof J; Shaw B. Allograft rejectionafter pediatric liver transplantation. Annual meeting of the Transplant Society; 1996.61. Kaufman S; Dhawan A; Vanderhoof J; Wisecarver J; Radio S; Markin R; Fox I; Heffron T; SudanD; Pillen T; Langnas A. Correlation of mucosal disaccharidase activities with histology inevaluation of rejection following intestinal transplantation. J Pediatr Gastroenterol; 23:374;1996.62. Roberts CA; Markin RS; Wisecarver JL; Radio SL. Malignant tumors in 894 consecutiveexplanted native livers: The University of Nebraska experience. US/CAP Mod Path, 11:156A,1998.63. Wickert RS; Rubocki R; Wisecarver J; Dominguez E; Hinrichs S. A DNA amplification basedassay designed to quantitate cytomegalovirus. Annual meeting for Molecular Pathologists;November 6-8; 1998; Washington DC.64. Walter TM; VonEssen SG; Reed EC; Tarantolo SR; Bishop MR; Rennard SI; Wisecarver JL.Induced sputum for CMV surveillance in allogeneic stem cell transplants. ALA/ATSInternational Conference; April 23-28; 1999; San Diego; CA.65. Radio SJ; Roberts CA; Wisecarver JL; Markin RS; Langans A; Sudan D. Pathology of explantedsmall bowel allografts. VI International Small Bowel Transplant Symposium; October 6-8;1999; Omaha; NE; (Submitted; May; 1999).66. Roberts CA; Markin RS; Radio SJ; Wisecarver JL; Langnas A. Histopathologic evaluation ofprimary intestinal transplant recipients at autopsy: a single center experience. VIInternational Small Bowel Transplant Symposium; October 6-8; 1999; Omaha; NE; (Submitted;May; 1999).

James L. Wisecarver, M.D., Ph.D.Page 1267. McCue BJ; Rubocki RJ; Shepherd SH; Wisecarver JL. Multiple alleles at four STR loci:contamination or ...? 10th International Symposium on Human Identification; September 29-October 1; 1999; Orlando; FL (Submitted).68. Rubocki RJ; Duffy KJ; Shepard KL; McCue BJ; Shepherd SJ; Wisecarver JL. Loss ofheterozygosity detected in a short tandem rpead (STR) locus commonly used forhuman DNAidentification. 10th International Symposium on Human Identification; September 29-October1; 1999; Orlando; FL (Submitted).69. Rubocki R; Duffy K; McCue B; Wisecarver J. Unusual STR profile in fraternal twins.Association for Molecular Pathology; November 5-7; 1999; St. Louis; MO (Submitted).70. Radio SJ; Roberts CA; Wisecarver JL. Vascular pathology in small bowel allograft explants.US/CAP; March 25-31; 2000; New Orleans; LA. (Submitted September; 1999).71. Oncracek TC; Rubocki R; Wisecarver J. Genetic loci commonly used in identity testing are subjetto deletion in neoplastic tissues. US/CAP; March 25-31; 2000; New Orleans; LA. (SubmittedSeptember; 1999).72. Wan X; Rubocki R; Kaufman S; Horslen S; Wisecarver J. Adenovirus infection in small bowelallografts: detection in paraffin-embedded tissue sections using polymerase chain reaction.US/CAP; March 25-31; 2000; New Orleans; LA. (Submitted September; 1999).OTHER PRESENTATIONS:Video microscopy: Quantitative immunohistochemistry and immunofluorescence micoscopy.Presented at the Scientific Symposium, ASCP 1990 Fall meeting, Dallas TX, October 29, 1990Molecular parentage testing. presented at annual meeting of Nebraska Courtroom ReportersAssociation, Mahoney State Park, NE, June 29th, 1993.Post-transplant monitoring of liver, pancreas and small intestinal allografts. Presented at theMidwest Regional ASHI Meeting, April 18, 19, 1993; Omaha, Nebraska.The Pathology Interest Group: a tool for recruiting medical students into pathology ProgramDirectors Session, fall ASCP Meeting - Orlando FL; October 1993Practical diagnostic aspects of liver, pancreas and small bowel transplantation. A workshoppresented at the fall ASCP/CAP meeting in Orlando, FL; October 1993Molecular Methods for Determining Identity: Applications in Parentage Testing,Transplantation and Forensic Medicine. New Technology Symposium, ASCP Matrix Meeting,November 12, 1993.Symposium Director; Present and Future Applications of New Technology: The Expanding Roleof Molecular Biology in Forensic Medicine and Parentage Testing. Spring ASCP/CAP Meeting,Seattle, April, 1994.PRODS Program Workshop Director - Innovative Ways of Teaching Clinical Pathology toPathology Residents. 1994 PRODS Meeting, Snowmass, CO.The Role of the Clinical Immunology Laboratory in Hematologic and Solid OrganTransplantation. University of Texas Teleconference network, August 23, 1994.

James L. Wisecarver, M.D., Ph.D.Page 13Molecular Diagnostics as Applied to Identification Testing. ASCP Clinical ChemistryPotpourri, Spring 1995 ASCP/CAP Meeting, Orlando,FL.PRODS Program Workshop Director - The Computer, What is its Role in Resident Education.1995 PRODS Meeting, Vail, CO.DNA testing for the molecularly challenged. Mini seminar; Fall 1995 meeting of ASCP/CAP;September, 19, 1995; New Orleans, LA.DNA testing for the molecularly challenged. Workshop; Fall 1996 meeting of ASCP/CAP;September, 1996; San Diego, CA.Forensics DNA Testing; Seminar at Nebraska County Attorney’s Spring Meeting, April, 1997,Kearney, NE.DNA testing for the molecularly challenged. Workshop; Fall 1996 meeting of ASCP/CAP;September, 20, 1997; Philadelphia, PA.Molecular Diagnostics in Clinical Medicine. Presented as part of the Lab medicine into the 21 stCentury. Encino-Tarzana Regional Medical Center, Tarzana, CA, October 26, 1998.Introduction to Clinical Molecular Diagnostics. A workshop presented at the ASCP Workshopin Medical Technology, Anaheim, CA, February 15, 2000.